Browse

Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study

Cited 8 time in Web of Science Cited 11 time in Scopus
Authors
Kim, Yeul Hong; Chung, Hyun Cheol; Kang, Won Ki; Park, Sook Ryun; Kim, Chul Soo; Kim, Tae-Yue; Shin, Sang Won; Park, Byung-Joo; Cha, Soo Jin; Bang, Yung-Jue
Issue Date
2008
Publisher
Springer Verlag
Citation
Cancer Chemother Pharmacol 62:263-270
Keywords
Adenocarcinoma/*drug therapy/mortality/pathologyAntineoplastic Combined Chemotherapy Protocols/administration &dosage/adverse effects/*therapeutic useCisplatin/administration & dosage/adverse effects/therapeutic useDisease-Free SurvivalGlutamates/administration & dosage/adverse effects/therapeutic useGuanine/administration & dosage/adverse effects/analogs &derivatives/therapeutic useInfusions, IntravenousKoreaNeoplasm InvasivenessStomach Neoplasms/*drug therapy/mortality/pathology
Abstract
BACKGROUND: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. PATIENTS AND METHODS: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) day 1, every 3 weeks plus folic acid and vitamin B(12) supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. RESULTS: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6-40.3%) and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2-4.4 months), and median overall survival was 6.6 months (95% CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles). CONCLUSION: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.
ISSN
0344-5704 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17960386

http://hdl.handle.net/10371/23634
DOI
https://doi.org/10.1007/s00280-007-0600-y
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Clinical Pharmacology (협동과정-임상약리학전공)Journal Papers (저널논문_협동과정-임상약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse